Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India

Severe asthma can be associated with eosinophilic or allergic phenotypes or both. Eosinophilic inflammation is associated with exacerbations and disease severity due to biological activity of interleukin‐5 (IL‐5). Patients with severe asthma have reported reduced lung function and poor health‐relate...

Full description

Saved in:
Bibliographic Details
Published in:Respirology case reports 2021-08, Vol.9 (8), p.e00780-n/a
Main Authors: Maturu, Venkata Nagarjuna, Meshram, Priti, Das, Soumya, Rajput, Ashok Kumar, Kotaru, Arun Chowdary, Kotak, Bhavesh, Markandeywar, Neeraj, Chhatwal, Simran
Format: Article
Language:English
Subjects:
Airway management
Asthma
Asthma control
Case reports
Case Series
Coronaviruses
COVID-19
eosinophilic inflammation
Immunoglobulins
Laboratories
mepolizumab
Monoclonal antibodies
Patients
Quality of life
Questionnaires
severe asthma
severe eosinophilic asthma
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe asthma can be associated with eosinophilic or allergic phenotypes or both. Eosinophilic inflammation is associated with exacerbations and disease severity due to biological activity of interleukin‐5 (IL‐5). Patients with severe asthma have reported reduced lung function and poor health‐related quality of life (HRQoL) and may require systemic corticosteroids for its management. Thus, treatment targeting IL‐5 can help improve quality of life and reduce the use of systemic corticosteroids in severe asthma. Mepolizumab is approved for treating severe eosinophilic asthma as it helps reduce exacerbations, improve lung function and asthma control, and reduce the use of systemic glucocorticoids. This further helps in enhancing HRQoL of these patients. This case series includes four adult patients suffering from severe eosinophilic asthma who were treated with mepolizumab. Severe asthma can be associated with eosinophilic or allergic phenotypes or both. Mepolizumab is a humanized monoclonal antibody approved for the treatment of severe eosinophilic asthma. This case series includes four adult patients suffering from severe eosinophilic asthma who were treated with mepolizumab.
ISSN:2051-3380
2051-3380
DOI:10.1002/rcr2.780